<DOC>
	<DOC>NCT00401375</DOC>
	<brief_summary>To evaluate the safety and efficacy of MNTX in patients who have undergone segmental colectomy and to assess if the time between the end of surgery and the first bowel movement is significantly shorter in the MNTX regimen than the equivalent assessment using a placebo regimen.</brief_summary>
	<brief_title>Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI).</brief_title>
	<detailed_description />
	<mesh_term>Ileus</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>Selected Male and female patients at least 18 years of age Patients must meet ASA physical status I, II, or III Patient must sign an ICF Patients must be scheduled for a segmental colectomy Females of childbearing potential must have a negative serum pregnancy test at the screening visit Negative for history of chronic active hepatitis B, HCV or HIV infection Selected Patients who received any investigational new drug in the previous 30 days Females who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>